Abstract 4232
Background
Pediatrics and AYA patients with cancer care often reported to receive high intensity medical care at the end-of-life. Especially, one study showed that Taiwanese children are more likely to receive high intensity care within one month from death than Canadian children. In this study, we investigate the current condition of end-of-life care for pediatrics, AYA patients who died at the hospital in Japan.
Methods
Using a multicenter administrative claims database, we identified patients with cancer aged 17 years or younger who died in hospital between July 2012 and March 2017 from 303 acute care hospitals in Japan. Patients’ data included age, gender, diagnosis, length of stay (LOS), use of opioids, the factors related to high-intensity end-of-life care (H-EOL), which comprised factors as follows; iv chemotherapy within 14 days from death, intensive care unit admission, more than one emergency department (ED) visit, more than 14 days hospital admission, and respiratory ventilation within one month from death.
Results
A total of 106 patients who died in 47 hospitals were included. The median age was 9 (0-17) years old and 57 patients (54%) were boys. Patients had brain tumor (n = 37), solid tumor (n = 30), hematologic malignancy (n = 25), other (n = 14). The average LOS was 60 (0-428 days). Fifty-five patients received opioids within 2weeks before their death. Ten patients received home medical care treatment before their death in the hospitals. Iv chemotherapy within 14 days from death was 25 patients (23.6%), intensive care unit admission within one month from death was 17 patients (16.0%), more than one ED visit within one month from death was 70 patients (66.0%), more than 14 days hospital admission was 69 patients (65.0%), and respiratory ventilation within one month from death was 20 patients (18.9%). Forty patients received one, 49 patients received two, 10 patients received three, 5 patients received four H-EOL care factors, respectively. Totally, 98% of patients had at least one H-EOL care factor.
Conclusions
Our study clarified the current situation of end-of-life care in the field of pediatrics, AYA with cancer. The proportion of H-EOL care in Japan is similar to that in Taiwan, and higher compared with that in Canada.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract